About : Verenium Board of Directors

Dr. James H. Cavanaugh has been a director of Verenium since 1992 and Verenium’s Chairman since 1998. Since 1988, Dr. Cavanaugh has served as a general partner of HealthCare Ventures LLC, a venture capital management company. Dr. Cavanaugh was formerly president of SmithKline & French Laboratories—U.S., the pharmaceutical division of SmithKline Beckman Corporation. Previously, he was president of SmithKline Beckman’s clinical laboratory business and, before that, president of Allergan International, a pharmaceutical company. Prior to his industry experience, Dr. Cavanaugh served in numerous senior posts with the U.S. Government on the White House Staff as staff assistant to the President for Health Affairs and then deputy director of the Domestic Council. He also served as deputy assistant to the President for Domestic Affairs and deputy chief of the White House staff. Prior to that, he was a member of the faculty of College of Medicine and the Graduate College at the University of Iowa.

Mr. John F. Dee has been a director of Verenium since May 2008. He is currently Chairman of the Board of Neurophage, Inc., a pioneering neuroscience company focused on neurodegenerative disorders. He also serves as Chairman of the Board of Bioprocessors, Inc., a leading innovator focused on advancements in bioprocessing for the Life Sciences industry. Previously, he served as President and Chief Executive Officer of Hypnion, Inc. from its founding in 200 until its sale to Eli Lilly in 2007 for $315 million. Under Mr. Dee’s leadership, Hypnion raised approximately $70 million in venture capital, built a world-class scientific team and technology platform, advanced 5 drugs into clinical trials, and positioned itself as the leader in sleep discorder research and development. Prior to Hypnion, Mr. Dee spent a significant portion of is professional career with McKinsey & Co., Inc., where he conducted performance-improvement and strategic growth initiatives for several major energy and pharmaceutical companies. After leaving McKinsey in 1997, he conducted “turnarounds” of biotechnology companies as an acting Chief Executive Officer, including a successful restructuring of Genta, Inc. In non-profit pursuits, Mr. Dee led a group of Bay Area economists and business leaders in a diagnostic and public policy review of the San Francisco Bay Area’s economic performance. He also advised the Pacific Presidio Center, a non-profit environmental group, on the potential redesign of the Presidio army base into a world environment center. Mr. Dee holds an M.S. in Engineering from Stanford University and an M.B.A. from Harvard University.

Mr. Peter Johnson has been a director of Verenium since 1999. Mr. Johnson was a founder of Agouron Pharmaceuticals, Inc. and served as its president and chief executive officer from its inception in 1984 until 2000. Mr. Johnson currently serves as a director of a nonprofit organization. Mr. Johnson received a B.A. and an M.A. from the University of California.

Dr. Fernand Kaufmann has been a director of Verenium since 2004. Dr. Kaufmann retired from The Dow Chemical Company, a public chemical manufacturing company, in 2001. During his over 33-year career at Dow, Dr. Kaufmann served in a number of senior executive capacities, including Group Vice-President for New Businesses and as a member of Dow’s management executive committee. Dr. Kaufmann currently serves as chief executive officer and chairman of the board of HPL SA, a Swiss technology start-up company in the field of novel lithium-ion battery technology. He also serves as an advisor to Emerald Technology Ventures, a Swiss venture capital fund focused on clean energy and other technology. Dr. Kaufmann received a Ph.D. in Polymer Chemistry from the University of Strasbourg, France.

Mr. Mark Leschly has been a director of Verenium since 1999. Mr. Leschly is a Managing Partner of Rho Capital Partners, Inc., an investment and venture capital management company, a position he has held since 1999. From 1994 to 1999, Mr. Leschly was an associate and then a general partner of HealthCare Ventures LLC, a health care venture capital management company. Prior to joining HealthCare Ventures, Mr. Leschly served as a consultant for McKinsey & Company, a management consulting company. Mr. Leschly also serves as a director for Tercica, Inc. and NitroMed, Inc. Mr. Leschly holds a B.A. degree from Harvard University and an M.B.A. from the Stanford Graduate School of Business.

Mr. Simon Rich has served as a director of Verenium since March 12, 2008. Mr. Rich is CEO of Fuqua Rich Weeks, a private equity partnership focused in the energy sector. He spent more than 15 years with the Louis Dreyfus Group where he held various positions, beginning with Executive Vice President of Louis Dreyfus Energy; Chairman, Chief Executive Officer of Louis Dreyfus Natural Gas; and Chief Operating Officer and Managing Director of Duke-Louis Dreyfus, a joint venture between Duke Energy and Louis Dreyfus Group. He then went on to become President of Louis Dreyfus Holding Company. During Mr. Rich's tenure with the Louis Dreyfus Group, he helped build the company into a major petroleum products distributor and oil refiner in the US and Europe. Mr. Rich then created Louis Dreyfus Natural Gas, which was taken public in 1993 on the New York Stock Exchange (NYSE) and merged with Dominion Resources in 2001. Mr. Rich also started EDF Trading in 1999, originally a joint venture of Louis Dreyfus and Electricité de France, an energy merchant in Europe with the responsibility for the economic dispatch of the French electric system. Mr. Rich currently teaches at the Nicholas School of the Environment and Earth Sciences at Duke University, where he formerly chaired the board of visitors. His current affiliations include Chairman of the Environmental Defense Fund of North Carolina and Chairman for the Center for Environmental Farming Systems. Mr. Rich is a graduate of Duke University.

Mr. Carlos A. Riva has been Verenium’s President, Chief Execuitve Officer and a director since 2007. Prior to Verenium’s merger with Celunol, Mr. Riva was the Chairman and Chief Executive Officer of Celunol since 2006. Prior to joining Celunol, from 2003 to 2005 Mr. Riva served as Executive Director of Amec plc, a major global construction and engineering company based in the U.K., where he was responsible for the company’s operations in the United States and Britain and for Amec’s global oil and gas business strategy. From 1995 to 2003, Mr. Riva was Chief Executive Officer of InterGen, a Boston-based joint venture between Shell and Bechtel that developed more than 18,000 megawatts of electric generating capacity, along with gas storage and pipelines, on six continents. Under his leadership InterGen raised $9 billion of non-recourse project financing to construct power projects and grew from a development company concept to a successful, global operating business. From 1992 to 1994, Mr. Riva was President and Chief Operating Officer of Boston-based J. Makowski Company, which developed the first independent power project in the United States. Mr. Riva received his S.B. and M.S. degrees in Civil Engineering from M.I.T. and Stanford University respectively, and an M.B.A. from the Harvard Business School.

Mr. Joshua Ruch has served as a director of Verenium since 2007, and prior to Verenium’s merger with Celunol, was a director of Celunol. Mr. Ruch is the Chairman and Chief Executive Officer of Rho Capital Partners, Inc., an investment and venture capital management company, which he co-founded in 1981. Prior to founding Rho, Mr. Ruch was employed in investment banking at Salomon Brothers. Mr. Ruch received a B.S. degree in electrical engineering from the Israel Institute of Technology (Technion) and an MBA from the Harvard Business School. Mr. Ruch is also a director of Genvec, Inc. (Nasdaq: GNVC) and a number of private companies.

Ms. Cheryl Wenzinger has been a director of Verenium since 2004 and serves as the chair of Verenium’s audit committee and as the audit committee’s financial expert. In her most recent position as audit partner at Deloitte & Touche from 1984 to 2000, Ms. Wenzinger served many private and public companies, with a focus on health care providers and insurers, manufacturing, and agribusiness. She currently serves on the Board of Directors for Banner Health, where she chairs the audit committee, and the Board of Trustees for Delta Dental Plan of Colorado, where she serves on the audit committee as the financial expert. Ms. Wenzinger received a B.S. in Accounting from the University of Northern Colorado and is a Certified Public Accountant.

Mr. Michael Zak has been a director of Verenium since 2007, and prior to Verenium’s merger with Celunol, was a director of Celunol. Since 1991 Mr. Zak has been with Charles River Ventures, a venture capital management company, where he invests in alternative energy and fuel technologies among other industries including voice and data communications equipment, networking software, applications software and services, optical communications equipment, network monitoring and analysis software, semiconductors and wireless communications equipment. From 1986 to 1991 he served as co-founder and Vice President of Concord Communications, a start-up network monitoring and analysis software company which subsequently became a successful investment of Charles River Ventures. From 1981 to 1986 Mr. Zak was employed by Motorola, Inc. and McKinsey & Company, Inc., and from 1975 to 1979 he served as a communications and signals intelligence officer in the United States Marine Corps. Mr. Zak holds a B.S. degree in engineering from Cornell University and an M.B.A. from the Harvard Business School.